内脏胸膜侵犯的非小细胞肺癌复发:一项随机临床试验的二次分析
CALGB 140503随机多中心非劣效试验的二次分析,比较肺叶与亚肺叶切除后病理升级为pT2(因内脏胸膜侵犯)的小外周NSCLC(≤2 cm)患者的生存与复发。pT2(VPI)患者的无病生存和复发无病生存均差于pT1(无VPI),复发率更高,且与切除范围无关。
要点
- pT2(VPI)患者5年无病生存53.3%,低于pT1(无VPI)的65.9%(分层log-rank P=0.02)。
- pT2(VPI)患者5年复发无病生存58.2%,低于pT1的73.1%(分层log-rank P=0.01)。
- 无病生存和复发无病生存均未见肺叶与亚肺叶切除组间差异。
核心结论
- 与无VPI的肿瘤患者相比,伴VPI的肿瘤患者无病生存和复发无病生存更差,局部和远处复发率更高;这些高复发率与肺实质切除范围无关,数据支持将此类患者纳入辅助治疗试验。
研究设计与样本
- CALGB 140503为随机多中心非劣效试验,纳入697例临床分期T1N0的小外周NSCLC患者。
- 2007年6月至2017年3月在83家参与机构入组,中位随访7年。
主要发现
- 679例参与者中390例(57.4%)为女性,中位(范围)年龄67.8(37.8-89.7)岁。
- 697例随机患者中566例(81.2%)为pT1(无VPI),113例(16.2%)为pT2(VPI)。
- pT1患者5年无病生存65.9%(95%CI 61.9%-70.2%),pT2患者为53.3%(95%CI 44.3%-64.1%)(分层log-rank P=0.02)。
- pT1患者复发27.6%(仅局部60例[10.8%];仅远处81例[14.6%]),pT2患者复发41.6%(仅局部17例[15.0%];仅远处27例[23.9%])。
- pT1肿瘤5年复发无病生存73.1%(95%CI 69.2%-77.1%),pT2肿瘤为58.2%(95%CI 49.2%-68.8%)(分层log-rank P=0.01)。
关键数值与推荐
- pT1肿瘤5年无病生存65.9%(95%CI 61.9%-70.2%)vs pT2肿瘤53.3%(95%CI 44.3%-64.1%),pT2较pT1降低。
- pT1肿瘤5年复发无病生存73.1%(95%CI 69.2%-77.1%)vs pT2肿瘤58.2%(95%CI 49.2%-68.8%),pT2较pT1降低。
- pT1复发27.6% vs pT2复发41.6%,pT2较pT1升高。
临床怎么用
- 作者认为这些数据支持将伴VPI的小外周NSCLC患者纳入辅助治疗试验。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The randomized clinical trial Cancer and Leukemia Group B (CALGB) 140503 showed that for patients with clinically staged T1N0 non-small cell lung cancer (NSCLC; ≤2 cm), sublobar resections were associated with similar oncological outcomes to those after lobar resection. The association of the extent of parenchymal resection with recurrence and survival in patients with tumors pathologically upstaged to T2 based on visceral pleural invasion (VPI) is controversial. OBJECTIVE: To determine survival and recurrence rates in patients with small peripheral pT2 NSCLC (≤2 cm) that was treated by either lobar or sublobar resection in CALGB 140503. DESIGN, PARTICIPANTS, AND SETTING: CALGB 140503, a randomized multicenter noninferiority trial, included 697 patients with small peripheral NSCLC that was clinically staged as T1N0. Enrollment was from June 2007 through March 2017 at 83 participating institutions, and after a median follow-up of 7 years, the primary outcome of disease-free survival after sublobar resection was noninferior to that after lobar resection. INTERVENTION: Lobar or sublobar resection. MAIN OUTCOMES AND MEASURES: Survival end points were estimated by the Kaplan-Meier estimator. Hazard ratios and 95% CIs were estimated using stratified Cox proportional hazard models. RESULTS: Of 679 participants, 390 (57.4%) were female, and the median (range) age was 67.8 (37.8-89.7) years. Among 697 patients randomized, 566 (81.2%) had pT1 tumors (no VPI) and 113 (16.2%) had pT2 tumors (VPI). Five-year disease-free survival was 65.9% (95% CI, 61.9%-70.2%) in patients with pT1 compared with 53.3% (95% CI, 44.3%-64.1%) in patients with pT2 tumors (stratified log-rank: P = .02). Disease recurrence developed in 27.6% of patients with pT1 (locoregional only: 60 [10.8%]; distant only: 81 [14.6%]) and 41.6% of those with pT2 (locoregional only: 17 [15.0%]; distant only: 27 [23.9%]). Five-year recurrence-free survival was 73.1% (95% CI, 69.2%-77.1%) for pT1 tumors and 58.2% (95% CI, 49.2%-68.8%) for pT2 tumors (stratified log-rank: P = .01). There were no intergroup differences in disease-free or recurrence-free survival based on the extent of parenchymal resection. CONCLUSIONS AND RELEVANCE: The results of this secondary analysis suggest that compared with patients with tumors without VPI, patients who had tumors with VPI had worse disease-free and recurrence-free survival and a higher rate of local and distant disease recurrence. These high rates of recurrence were independent of the extent of parenchymal resection, and these data support the inclusion of these patients in adjuvant therapy trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT0049933.
引用
- Altorki N, Wang X, Damman B, et al. Recurrence of Non-Small Cell Lung Cancer With Visceral Pleural Invasion: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2024. PMID: 39088196. doi:10.1001/jamaoncol.2024.2491
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。